Aquestive Therapeutics (AQST) Change in Account Payables (2020 - 2026)

Aquestive Therapeutics' Change in Account Payables history runs 7 years deep, the most recent figure standing at -$18.0 million for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 1043.46% year-over-year to -$18.0 million in Q1 2026; TTM through Mar 2026 was -$355000.0, a 110.43% decrease from a year earlier, with the FY2025 full-year figure at $19.5 million, up 601.76% from the prior year.
• Change in Account Payables slipped to -$18.0 million in Q1 2026 per AQST's latest filing, from $19.2 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $19.2 million in Q4 2025 and bottomed at -$18.0 million in Q1 2026.
• The 5-year median for Change in Account Payables is $182000.0 (2022), against an average of $290882.4.
• Across the five-year window, Change in Account Payables surged 1270.33% in 2023 and slumped 1043.46% in 2026, its largest moves.
• Year by year, Change in Account Payables stood at -$1.1 million in 2022, then gained by 5.07% to -$1.1 million in 2023, then surged by 346.82% to $2.6 million in 2024, then jumped by 630.16% to $19.2 million in 2025, then sank by 193.38% to -$18.0 million in 2026.
• Per Business Quant, the three latest AQST Change in Account Payables figures stand at -$18.0 million (Q1 2026), $19.2 million (Q4 2025), and -$1.3 million (Q3 2025).